Weill Cornell Researchers Reverse Engineer Ketamine's Antidepressant Mechanism, Paving Way for Safer Alternatives

Weill Cornell Medicine investigators have successfully "reverse engineered" ketamine's antidepressant effects, identifying the precise molecular mechanisms that could lead to safer, more effective treatments for depression. The breakthrough research, published in two complementary studies in Cell and Science Advances, offers hope for the approximately one-third of patients who suffer from treatment-resistant depression.

Targeting the Brain's Master Regulators

The research team, led by Dr. Conor Liston, the Robert Michels, M.D. Professor of Psychiatry at Weill Cornell Medicine, and Dr. Joshua Levitz, professor of biochemistry and biophysics, focused on understanding exactly how ketamine produces its rapid antidepressant effects. Their Cell study, published April 23, revealed that ketamine targets a specific subset of opioid receptors on specialized brain cells called interneurons in the prefrontal cortex.

"Ketamine targets these opioid receptors, relieving inhibition by the interneurons and reactivating prefrontal cortex cells for a very brief period of time—maybe only for 15 or 20 minutes," explained Dr. Levitz. "That seems to be enough to kickstart this whole program of cortical reawakening."

The interneurons normally act as master regulators of brain cell activity in the prefrontal cortex, a region crucial for emotion, attention, and behavior. However, excessive stress causes these cells to become hyperactive, suppressing overall brain activity and contributing to depression. Ketamine reverses this effect by stimulating opioid receptors to reduce the interneurons' excessive activity.

A Triple-Drug Strategy Shows Promise

Perhaps most significantly, the researchers demonstrated they could recreate ketamine's antidepressant effects in mice using a combination of small doses of three existing drugs that target the same pathway. This synergistic approach could potentially deliver rapid antidepressant benefits while avoiding the problematic side effects associated with ketamine's higher doses.

"This synergistic strategy could produce rapid antidepressant effects at much lower doses of each compound," said Dr. Liston, who is also a psychiatrist at NewYork-Presbyterian/Weill Cornell Medical Center. "By avoiding higher doses, we can avoid side effects."

Understanding Long-Term Benefits

The second study, published May 1 in Science Advances, explored ketamine's longer-term antidepressant effects through a collaboration with Dr. Francis Lee, chair of psychiatry at Weill Cornell Medicine. This research confirmed that cross-talk between two specific receptors—TrkB and mGluR5—is essential for maintaining ketamine's antidepressant benefits.

The study revealed that brain-derived neurotrophic factor (BDNF), a protein that promotes brain cell survival and growth, stimulates the TrkB receptor and promotes interaction with the mGluR5 receptor. This interaction strengthens connections between brain cells while simultaneously removing the cell's ability to weaken those connections again.

"Drugs that drive these interactions strengthen all the brain connections that have been weakened during depression, which helps promote initial and longer-term antidepressant effects," Dr. Levitz explained. "It both makes the brain connections stronger and removes the ability to weaken brain connections."

Accelerated Path to Clinical Testing

The research team is preparing to launch clinical trials testing whether combining small doses of existing drugs can recreate the antidepressant effects observed in their laboratory studies. Because the researchers are using drugs already proven safe and effective in humans, the development timeline could be significantly accelerated.

"If that's true, we could get these new therapies to patients on an accelerated timeline," Dr. Liston noted.

Dr. Lee and Dr. Levitz are also continuing to study whether combining low doses of existing drugs that target mGluR5 receptors with low doses of ketamine might deliver lasting antidepressant effects with fewer side effects, with plans to eventually launch additional clinical trials.

Addressing an Urgent Medical Need

The research addresses a critical gap in depression treatment. While many effective treatments exist, about one-third of patients must try multiple medications before finding relief, and another third have treatment-resistant depression. Ketamine can provide immediate relief for some patients with treatment-resistant depression, but its effects are often short-lived and it carries serious side effects including cardiovascular changes, dissociation, and addiction potential.

"We really need new treatments," Dr. Liston emphasized. "By understanding how ketamine works, we hoped to find new ways of achieving similar antidepressant effects rapidly, without some of those side effects."

The multidisciplinary approach, combining expertise in clinical psychiatry, molecular signaling, and biochemistry, has facilitated the rapid translation of these findings toward clinical applications. As Dr. Lee noted, "These two studies together reframe how we think about how ketamine works for our patients. It shows patients that we are making progress towards innovative therapies and will help them understand the treatments they are receiving."